<?xml version="1.0" encoding="UTF-8"?>
<p>A lack of balance also exists in the nature of the partners involved in TB vaccine R&amp;D, as support from non-profit organizations, such as the BMGF, and governments far outweigh the involvement of commercial entities such as established pharmaceutical companies and smaller biotech companies. Additionally, the shortage of funding has resulted in a lack of academic partners and new researchers entering the field. Moving forward, it will be important to create incentives for industry to increase activity in TB vaccine development initiatives.</p>
